Document is current
Any future updates will be listed below
-
Authors
Rogeau, Antoine https://orcid.org/0000-0002-3993-3954
Nordio, Giovanna
Veronese, Mattia https://orcid.org/0000-0003-3562-0683
Brown, Kirsten
Nour, Matthew M. https://orcid.org/0000-0003-0858-6184
Osugo, Martin
Jauhar, Sameer https://orcid.org/0000-0002-3878-3659
Howes, Oliver D.
McCutcheon, Robert A. https://orcid.org/0000-0003-1102-2566
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research
Wellcome Trust (215747/Z/19/Z, 102186/B/13/Z, 094849/Z/10/Z, 200102/Z/15/Z)
RCUK | Medical Research Council (MC_U120097115)
Maudsley Charity (666)
- License Information
-
More Information
Article History
Received: 25 November 2021
Revised: 14 April 2022
Accepted: 21 April 2022
First Online: 11 May 2022
Competing interests
: RAM has received honoraria for educational talks from Otsuka and Janssen. ODH has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organized by Angellini, Astra-Zeneca, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Invicro, Janssen, Lundbeck, Lyden-Delta, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Recordati, and Roche. Neither ODH or his family have been employed by or have holdings/ a financial stake in any pharmaceutical company. MV has received consulting honoraria from GSK. ODH and MV hold a patent application for the use of dopamine imaging as a prognostic tool. SJ has received honoraria for educational talks from Sunovian and his employer (King’s College London) has received honoraria.
